Results 71 to 80 of about 3,923 (195)

Correction to: Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections [PDF]

open access: yesDrugs, 2018
The article Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections.
openaire   +2 more sources

Development of an HPLC Method for the Determination of Meropenem/Vaborbactam in Biological and Aqueous Matrixes

open access: yesJournal of Chromatographic Science, 2020
Abstract A HPLC method was developed and validated to analyze meropenem and vaborbactam simultaneously in murine plasma and saline matrixes. A 60-μL volume of extracted sample was injected onto a 5-μm BDS Phenyl-Hypersil C18 reversed-phase column and analyzed with a UV detector set at 298 nm for the first 4.9 min and switched to 240 nm ...
Christina A, Sutherland   +1 more
openaire   +2 more sources

Reversing Antibiotic Resistance: Strategies From Adjuvants to Innovative Therapeutics

open access: yesMicrobiologyOpen, Volume 15, Issue 1, February 2026.
Molecular reversal strategies against antibiotic resistance act through three mechanisms: inhibiting resistance gene function, blocking horizontal gene transfer, and modulating host defense. Emerging technologies, such as CRISPR‐Cas gene editing, photodynamic therapy, nanotechnology, and ecological competition, further strengthen these approaches ...
Tianjiao Li   +4 more
wiley   +1 more source

Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam

open access: yesMicrobiology Spectrum
With the introduction of ceftazidime-avibactam worldwide, the antimicrobial activity of new β-lactam/β-lactamase inhibitors (BL/BLIs) needs to be investigated.
Min Seo Kang   +13 more
doaj   +1 more source

Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis

open access: yes, 2018
The recently approved combination of meropenem and vaborbactam (Vabomere) is highly active against Gram-negative pathogens, especially Klebsiella pneumoniae carbapenemase (KPC)-producing, carbapenem-resistant ...
Kelly Peterson   +8 more
core   +1 more source

Outcomes and Predictors of Mortality in Patients With KPC-Kp Infections Treated With Meropenem Vaborbactam: An Observational Multicenter Study [PDF]

open access: yes
Background: Meropenem-vaborbactam is a recent and promising option for the treatment of KPC-producing Klebsiella pneumoniae (KPC-Kp) infections, including those resistant to ceftazidime-avibactam.
22   +46 more
core   +6 more sources

Carbapenem Resistance in India: A Systematic Review of Epidemiology, Diagnostic Strategies, and Therapeutic Approaches

open access: yesBioMed Research International, Volume 2026, Issue 1, 2026.
Background Carbapenem‐resistant gram‐negative infections pose a major public health challenge in India due to high antibiotic consumption, limited diagnostic access, and regional variation in resistance mechanisms. We systematically reviewed recent data to evaluate prevalence, diagnostics, and therapeutic strategies.
Akhil Kapoor   +12 more
wiley   +1 more source

Meropenem–vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria

open access: yes, 2018
Meropenem–vaborbactam is a fixed-dose combination product of a carbapenem and a cyclic boronic acid β-lactamase inhibitor with potent in vitro activity against Klebsiella pneumoniae carbapenemase-producing carbapenem-resistant Enterobacteriaceae (CRE ...
John P Mills   +3 more
core   +1 more source

Plasmid‐Mediated AmpC Detection in Escherichia coli and Klebsiella pneumoniae: In Vitro Prevalence and In Silico Inhibitor Design

open access: yesCanadian Journal of Infectious Diseases and Medical Microbiology, Volume 2026, Issue 1, 2026.
Objectives This study investigated the prevalence of AmpC beta‐lactamase‐producing Escherichia coli and Klebsiella pneumoniae in clinical specimens collected in Lahore, Pakistan, and aimed to identify potential inhibitors targeting AmpC beta‐lactamases. Methods A total of 17,500 clinical specimens were collected from June 2018 to June 2021 and analyzed
Muhammad Sarfraz   +10 more
wiley   +1 more source

Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem‐resistant Enterobacteriaceae [PDF]

open access: yesPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2018
Vaborbactam (VAB; formerly RPX7009) is a novel beta‐lactamase inhibitor based on a cyclic boronic acid pharmacophore with potent inhibitory activity against Ambler class A and C beta‐lactamases. It has been co‐formulated with meropenem to restore its activity against Klebsiella pneumoniae ...
Sarah Christina Jane Jorgensen   +1 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy